Global PET Radiopharmaceuticals Market Outlook and Growth Opportunities 2025
Description
Summary
According to APO Research, the global PET Radiopharmaceuticals market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for PET Radiopharmaceuticals is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for PET Radiopharmaceuticals is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the PET Radiopharmaceuticals market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for PET Radiopharmaceuticals is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the PET Radiopharmaceuticals market include Cardinal Health Inc. (U.S.), Bayer AG (Germany), Nordion, Inc. (Canada), Mallinckrodt plc (Ireland), Lantheus Medical Imaging, Inc. (U.S.), IBA Molecular Imaging (Belgium), GE Healthcare (U.K.), Eczacibasi-Monrol Nuclear Products (Turkey) and Bracco Imaging S.p.A (Italy), etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for PET Radiopharmaceuticals, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of PET Radiopharmaceuticals, also provides the sales of main regions and countries. Of the upcoming market potential for PET Radiopharmaceuticals, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the PET Radiopharmaceuticals sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global PET Radiopharmaceuticals market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for PET Radiopharmaceuticals sales, projected growth trends, production technology, application and end-user industry.
PET Radiopharmaceuticals Segment by Company
Cardinal Health Inc. (U.S.)
Bayer AG (Germany)
Nordion, Inc. (Canada)
Mallinckrodt plc (Ireland)
Lantheus Medical Imaging, Inc. (U.S.)
IBA Molecular Imaging (Belgium)
GE Healthcare (U.K.)
Eczacibasi-Monrol Nuclear Products (Turkey)
Bracco Imaging S.p.A (Italy)
Advanced Accelerator Applications S.A. (France)
PET Radiopharmaceuticals Segment by Type
F-18
Ru-82
Others
PET Radiopharmaceuticals Segment by Application
Neurology
Cardiology
Oncology
Others
PET Radiopharmaceuticals Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global PET Radiopharmaceuticals status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions PET Radiopharmaceuticals market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify PET Radiopharmaceuticals significant trends, drivers, influence factors in global and regions.
6. To analyze PET Radiopharmaceuticals competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PET Radiopharmaceuticals market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of PET Radiopharmaceuticals and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PET Radiopharmaceuticals.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the PET Radiopharmaceuticals market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global PET Radiopharmaceuticals industry.
Chapter 3: Detailed analysis of PET Radiopharmaceuticals manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of PET Radiopharmaceuticals in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of PET Radiopharmaceuticals in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Please Note:Â Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, the global PET Radiopharmaceuticals market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for PET Radiopharmaceuticals is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for PET Radiopharmaceuticals is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the PET Radiopharmaceuticals market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for PET Radiopharmaceuticals is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the PET Radiopharmaceuticals market include Cardinal Health Inc. (U.S.), Bayer AG (Germany), Nordion, Inc. (Canada), Mallinckrodt plc (Ireland), Lantheus Medical Imaging, Inc. (U.S.), IBA Molecular Imaging (Belgium), GE Healthcare (U.K.), Eczacibasi-Monrol Nuclear Products (Turkey) and Bracco Imaging S.p.A (Italy), etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for PET Radiopharmaceuticals, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of PET Radiopharmaceuticals, also provides the sales of main regions and countries. Of the upcoming market potential for PET Radiopharmaceuticals, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the PET Radiopharmaceuticals sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global PET Radiopharmaceuticals market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for PET Radiopharmaceuticals sales, projected growth trends, production technology, application and end-user industry.
PET Radiopharmaceuticals Segment by Company
Cardinal Health Inc. (U.S.)
Bayer AG (Germany)
Nordion, Inc. (Canada)
Mallinckrodt plc (Ireland)
Lantheus Medical Imaging, Inc. (U.S.)
IBA Molecular Imaging (Belgium)
GE Healthcare (U.K.)
Eczacibasi-Monrol Nuclear Products (Turkey)
Bracco Imaging S.p.A (Italy)
Advanced Accelerator Applications S.A. (France)
PET Radiopharmaceuticals Segment by Type
F-18
Ru-82
Others
PET Radiopharmaceuticals Segment by Application
Neurology
Cardiology
Oncology
Others
PET Radiopharmaceuticals Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global PET Radiopharmaceuticals status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions PET Radiopharmaceuticals market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify PET Radiopharmaceuticals significant trends, drivers, influence factors in global and regions.
6. To analyze PET Radiopharmaceuticals competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PET Radiopharmaceuticals market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of PET Radiopharmaceuticals and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PET Radiopharmaceuticals.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the PET Radiopharmaceuticals market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global PET Radiopharmaceuticals industry.
Chapter 3: Detailed analysis of PET Radiopharmaceuticals manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of PET Radiopharmaceuticals in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of PET Radiopharmaceuticals in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Please Note:Â Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
195 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global PET Radiopharmaceuticals Sales Value (2020-2031)
- 1.2.2 Global PET Radiopharmaceuticals Sales Volume (2020-2031)
- 1.2.3 Global PET Radiopharmaceuticals Sales Average Price (2020-2031)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
- 2 PET Radiopharmaceuticals Market Dynamics
- 2.1 PET Radiopharmaceuticals Industry Trends
- 2.2 PET Radiopharmaceuticals Industry Drivers
- 2.3 PET Radiopharmaceuticals Industry Opportunities and Challenges
- 2.4 PET Radiopharmaceuticals Industry Restraints
- 3 PET Radiopharmaceuticals Market by Company
- 3.1 Global PET Radiopharmaceuticals Company Revenue Ranking in 2024
- 3.2 Global PET Radiopharmaceuticals Revenue by Company (2020-2025)
- 3.3 Global PET Radiopharmaceuticals Sales Volume by Company (2020-2025)
- 3.4 Global PET Radiopharmaceuticals Average Price by Company (2020-2025)
- 3.5 Global PET Radiopharmaceuticals Company Ranking (2023-2025)
- 3.6 Global PET Radiopharmaceuticals Company Manufacturing Base and Headquarters
- 3.7 Global PET Radiopharmaceuticals Company Product Type and Application
- 3.8 Global PET Radiopharmaceuticals Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global PET Radiopharmaceuticals Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
- 3.9.3 2024 PET Radiopharmaceuticals Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
- 4 PET Radiopharmaceuticals Market by Type
- 4.1 PET Radiopharmaceuticals Type Introduction
- 4.1.1 F-18
- 4.1.2 Ru-82
- 4.1.3 Others
- 4.2 Global PET Radiopharmaceuticals Sales Volume by Type
- 4.2.1 Global PET Radiopharmaceuticals Sales Volume by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global PET Radiopharmaceuticals Sales Volume by Type (2020-2031)
- 4.2.3 Global PET Radiopharmaceuticals Sales Volume Share by Type (2020-2031)
- 4.3 Global PET Radiopharmaceuticals Sales Value by Type
- 4.3.1 Global PET Radiopharmaceuticals Sales Value by Type (2020 VS 2024 VS 2031)
- 4.3.2 Global PET Radiopharmaceuticals Sales Value by Type (2020-2031)
- 4.3.3 Global PET Radiopharmaceuticals Sales Value Share by Type (2020-2031)
- 5 PET Radiopharmaceuticals Market by Application
- 5.1 PET Radiopharmaceuticals Application Introduction
- 5.1.1 Neurology
- 5.1.2 Cardiology
- 5.1.3 Oncology
- 5.1.4 Others
- 5.2 Global PET Radiopharmaceuticals Sales Volume by Application
- 5.2.1 Global PET Radiopharmaceuticals Sales Volume by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global PET Radiopharmaceuticals Sales Volume by Application (2020-2031)
- 5.2.3 Global PET Radiopharmaceuticals Sales Volume Share by Application (2020-2031)
- 5.3 Global PET Radiopharmaceuticals Sales Value by Application
- 5.3.1 Global PET Radiopharmaceuticals Sales Value by Application (2020 VS 2024 VS 2031)
- 5.3.2 Global PET Radiopharmaceuticals Sales Value by Application (2020-2031)
- 5.3.3 Global PET Radiopharmaceuticals Sales Value Share by Application (2020-2031)
- 6 PET Radiopharmaceuticals Regional Sales and Value Analysis
- 6.1 Global PET Radiopharmaceuticals Sales by Region: 2020 VS 2024 VS 2031
- 6.2 Global PET Radiopharmaceuticals Sales by Region (2020-2031)
- 6.2.1 Global PET Radiopharmaceuticals Sales by Region: 2020-2025
- 6.2.2 Global PET Radiopharmaceuticals Sales by Region (2026-2031)
- 6.3 Global PET Radiopharmaceuticals Sales Value by Region: 2020 VS 2024 VS 2031
- 6.4 Global PET Radiopharmaceuticals Sales Value by Region (2020-2031)
- 6.4.1 Global PET Radiopharmaceuticals Sales Value by Region: 2020-2025
- 6.4.2 Global PET Radiopharmaceuticals Sales Value by Region (2026-2031)
- 6.5 Global PET Radiopharmaceuticals Market Price Analysis by Region (2020-2025)
- 6.6 North America
- 6.6.1 North America PET Radiopharmaceuticals Sales Value (2020-2031)
- 6.6.2 North America PET Radiopharmaceuticals Sales Value Share by Country, 2024 VS 2031
- 6.7 Europe
- 6.7.1 Europe PET Radiopharmaceuticals Sales Value (2020-2031)
- 6.7.2 Europe PET Radiopharmaceuticals Sales Value Share by Country, 2024 VS 2031
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific PET Radiopharmaceuticals Sales Value (2020-2031)
- 6.8.2 Asia-Pacific PET Radiopharmaceuticals Sales Value Share by Country, 2024 VS 2031
- 6.9 South America
- 6.9.1 South America PET Radiopharmaceuticals Sales Value (2020-2031)
- 6.9.2 South America PET Radiopharmaceuticals Sales Value Share by Country, 2024 VS 2031
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa PET Radiopharmaceuticals Sales Value (2020-2031)
- 6.10.2 Middle East & Africa PET Radiopharmaceuticals Sales Value Share by Country, 2024 VS 2031
- 7 PET Radiopharmaceuticals Country-level Sales and Value Analysis
- 7.1 Global PET Radiopharmaceuticals Sales by Country: 2020 VS 2024 VS 2031
- 7.2 Global PET Radiopharmaceuticals Sales Value by Country: 2020 VS 2024 VS 2031
- 7.3 Global PET Radiopharmaceuticals Sales by Country (2020-2031)
- 7.3.1 Global PET Radiopharmaceuticals Sales by Country (2020-2025)
- 7.3.2 Global PET Radiopharmaceuticals Sales by Country (2026-2031)
- 7.4 Global PET Radiopharmaceuticals Sales Value by Country (2020-2031)
- 7.4.1 Global PET Radiopharmaceuticals Sales Value by Country (2020-2025)
- 7.4.2 Global PET Radiopharmaceuticals Sales Value by Country (2026-2031)
- 7.5 USA
- 7.5.1 USA PET Radiopharmaceuticals Sales Value Growth Rate (2020-2031)
- 7.5.2 USA PET Radiopharmaceuticals Sales Value Share by Type, 2024 VS 2031
- 7.5.3 USA PET Radiopharmaceuticals Sales Value Share by Application, 2024 VS 2031
- 7.6 Canada
- 7.6.1 Canada PET Radiopharmaceuticals Sales Value Growth Rate (2020-2031)
- 7.6.2 Canada PET Radiopharmaceuticals Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Canada PET Radiopharmaceuticals Sales Value Share by Application, 2024 VS 2031
- 7.7 Mexico
- 7.6.1 Mexico PET Radiopharmaceuticals Sales Value Growth Rate (2020-2031)
- 7.6.2 Mexico PET Radiopharmaceuticals Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Mexico PET Radiopharmaceuticals Sales Value Share by Application, 2024 VS 2031
- 7.8 Germany
- 7.8.1 Germany PET Radiopharmaceuticals Sales Value Growth Rate (2020-2031)
- 7.8.2 Germany PET Radiopharmaceuticals Sales Value Share by Type, 2024 VS 2031
- 7.8.3 Germany PET Radiopharmaceuticals Sales Value Share by Application, 2024 VS 2031
- 7.9 France
- 7.9.1 France PET Radiopharmaceuticals Sales Value Growth Rate (2020-2031)
- 7.9.2 France PET Radiopharmaceuticals Sales Value Share by Type, 2024 VS 2031
- 7.9.3 France PET Radiopharmaceuticals Sales Value Share by Application, 2024 VS 2031
- 7.10 U.K.
- 7.10.1 U.K. PET Radiopharmaceuticals Sales Value Growth Rate (2020-2031)
- 7.10.2 U.K. PET Radiopharmaceuticals Sales Value Share by Type, 2024 VS 2031
- 7.10.3 U.K. PET Radiopharmaceuticals Sales Value Share by Application, 2024 VS 2031
- 7.11 Italy
- 7.11.1 Italy PET Radiopharmaceuticals Sales Value Growth Rate (2020-2031)
- 7.11.2 Italy PET Radiopharmaceuticals Sales Value Share by Type, 2024 VS 2031
- 7.11.3 Italy PET Radiopharmaceuticals Sales Value Share by Application, 2024 VS 2031
- 7.12 Spain
- 7.12.1 Spain PET Radiopharmaceuticals Sales Value Growth Rate (2020-2031)
- 7.12.2 Spain PET Radiopharmaceuticals Sales Value Share by Type, 2024 VS 2031
- 7.12.3 Spain PET Radiopharmaceuticals Sales Value Share by Application, 2024 VS 2031
- 7.13 Russia
- 7.13.1 Russia PET Radiopharmaceuticals Sales Value Growth Rate (2020-2031)
- 7.13.2 Russia PET Radiopharmaceuticals Sales Value Share by Type, 2024 VS 2031
- 7.13.3 Russia PET Radiopharmaceuticals Sales Value Share by Application, 2024 VS 2031
- 7.14 Netherlands
- 7.14.1 Netherlands PET Radiopharmaceuticals Sales Value Growth Rate (2020-2031)
- 7.14.2 Netherlands PET Radiopharmaceuticals Sales Value Share by Type, 2024 VS 2031
- 7.14.3 Netherlands PET Radiopharmaceuticals Sales Value Share by Application, 2024 VS 2031
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries PET Radiopharmaceuticals Sales Value Growth Rate (2020-2031)
- 7.15.2 Nordic Countries PET Radiopharmaceuticals Sales Value Share by Type, 2024 VS 2031
- 7.15.3 Nordic Countries PET Radiopharmaceuticals Sales Value Share by Application, 2024 VS 2031
- 7.16 China
- 7.16.1 China PET Radiopharmaceuticals Sales Value Growth Rate (2020-2031)
- 7.16.2 China PET Radiopharmaceuticals Sales Value Share by Type, 2024 VS 2031
- 7.16.3 China PET Radiopharmaceuticals Sales Value Share by Application, 2024 VS 2031
- 7.17 Japan
- 7.17.1 Japan PET Radiopharmaceuticals Sales Value Growth Rate (2020-2031)
- 7.17.2 Japan PET Radiopharmaceuticals Sales Value Share by Type, 2024 VS 2031
- 7.17.3 Japan PET Radiopharmaceuticals Sales Value Share by Application, 2024 VS 2031
- 7.18 South Korea
- 7.18.1 South Korea PET Radiopharmaceuticals Sales Value Growth Rate (2020-2031)
- 7.18.2 South Korea PET Radiopharmaceuticals Sales Value Share by Type, 2024 VS 2031
- 7.18.3 South Korea PET Radiopharmaceuticals Sales Value Share by Application, 2024 VS 2031
- 7.19 India
- 7.19.1 India PET Radiopharmaceuticals Sales Value Growth Rate (2020-2031)
- 7.19.2 India PET Radiopharmaceuticals Sales Value Share by Type, 2024 VS 2031
- 7.19.3 India PET Radiopharmaceuticals Sales Value Share by Application, 2024 VS 2031
- 7.20 Australia
- 7.20.1 Australia PET Radiopharmaceuticals Sales Value Growth Rate (2020-2031)
- 7.20.2 Australia PET Radiopharmaceuticals Sales Value Share by Type, 2024 VS 2031
- 7.20.3 Australia PET Radiopharmaceuticals Sales Value Share by Application, 2024 VS 2031
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia PET Radiopharmaceuticals Sales Value Growth Rate (2020-2031)
- 7.21.2 Southeast Asia PET Radiopharmaceuticals Sales Value Share by Type, 2024 VS 2031
- 7.21.3 Southeast Asia PET Radiopharmaceuticals Sales Value Share by Application, 2024 VS 2031
- 7.22 Brazil
- 7.22.1 Brazil PET Radiopharmaceuticals Sales Value Growth Rate (2020-2031)
- 7.22.2 Brazil PET Radiopharmaceuticals Sales Value Share by Type, 2024 VS 2031
- 7.22.3 Brazil PET Radiopharmaceuticals Sales Value Share by Application, 2024 VS 2031
- 7.23 Argentina
- 7.23.1 Argentina PET Radiopharmaceuticals Sales Value Growth Rate (2020-2031)
- 7.23.2 Argentina PET Radiopharmaceuticals Sales Value Share by Type, 2024 VS 2031
- 7.23.3 Argentina PET Radiopharmaceuticals Sales Value Share by Application, 2024 VS 2031
- 7.24 Chile
- 7.24.1 Chile PET Radiopharmaceuticals Sales Value Growth Rate (2020-2031)
- 7.24.2 Chile PET Radiopharmaceuticals Sales Value Share by Type, 2024 VS 2031
- 7.24.3 Chile PET Radiopharmaceuticals Sales Value Share by Application, 2024 VS 2031
- 7.25 Colombia
- 7.25.1 Colombia PET Radiopharmaceuticals Sales Value Growth Rate (2020-2031)
- 7.25.2 Colombia PET Radiopharmaceuticals Sales Value Share by Type, 2024 VS 2031
- 7.25.3 Colombia PET Radiopharmaceuticals Sales Value Share by Application, 2024 VS 2031
- 7.26 Peru
- 7.26.1 Peru PET Radiopharmaceuticals Sales Value Growth Rate (2020-2031)
- 7.26.2 Peru PET Radiopharmaceuticals Sales Value Share by Type, 2024 VS 2031
- 7.26.3 Peru PET Radiopharmaceuticals Sales Value Share by Application, 2024 VS 2031
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia PET Radiopharmaceuticals Sales Value Growth Rate (2020-2031)
- 7.27.2 Saudi Arabia PET Radiopharmaceuticals Sales Value Share by Type, 2024 VS 2031
- 7.27.3 Saudi Arabia PET Radiopharmaceuticals Sales Value Share by Application, 2024 VS 2031
- 7.28 Israel
- 7.28.1 Israel PET Radiopharmaceuticals Sales Value Growth Rate (2020-2031)
- 7.28.2 Israel PET Radiopharmaceuticals Sales Value Share by Type, 2024 VS 2031
- 7.28.3 Israel PET Radiopharmaceuticals Sales Value Share by Application, 2024 VS 2031
- 7.29 UAE
- 7.29.1 UAE PET Radiopharmaceuticals Sales Value Growth Rate (2020-2031)
- 7.29.2 UAE PET Radiopharmaceuticals Sales Value Share by Type, 2024 VS 2031
- 7.29.3 UAE PET Radiopharmaceuticals Sales Value Share by Application, 2024 VS 2031
- 7.30 Turkey
- 7.30.1 Turkey PET Radiopharmaceuticals Sales Value Growth Rate (2020-2031)
- 7.30.2 Turkey PET Radiopharmaceuticals Sales Value Share by Type, 2024 VS 2031
- 7.30.3 Turkey PET Radiopharmaceuticals Sales Value Share by Application, 2024 VS 2031
- 7.31 Iran
- 7.31.1 Iran PET Radiopharmaceuticals Sales Value Growth Rate (2020-2031)
- 7.31.2 Iran PET Radiopharmaceuticals Sales Value Share by Type, 2024 VS 2031
- 7.31.3 Iran PET Radiopharmaceuticals Sales Value Share by Application, 2024 VS 2031
- 7.32 Egypt
- 7.32.1 Egypt PET Radiopharmaceuticals Sales Value Growth Rate (2020-2031)
- 7.32.2 Egypt PET Radiopharmaceuticals Sales Value Share by Type, 2024 VS 2031
- 7.32.3 Egypt PET Radiopharmaceuticals Sales Value Share by Application, 2024 VS 2031
- 8 Company Profiles
- 8.1 Cardinal Health Inc. (U.S.)
- 8.1.1 Cardinal Health Inc. (U.S.) Comapny Information
- 8.1.2 Cardinal Health Inc. (U.S.) Business Overview
- 8.1.3 Cardinal Health Inc. (U.S.) PET Radiopharmaceuticals Sales, Value and Gross Margin (2020-2025)
- 8.1.4 Cardinal Health Inc. (U.S.) PET Radiopharmaceuticals Product Portfolio
- 8.1.5 Cardinal Health Inc. (U.S.) Recent Developments
- 8.2 Bayer AG (Germany)
- 8.2.1 Bayer AG (Germany) Comapny Information
- 8.2.2 Bayer AG (Germany) Business Overview
- 8.2.3 Bayer AG (Germany) PET Radiopharmaceuticals Sales, Value and Gross Margin (2020-2025)
- 8.2.4 Bayer AG (Germany) PET Radiopharmaceuticals Product Portfolio
- 8.2.5 Bayer AG (Germany) Recent Developments
- 8.3 Nordion, Inc. (Canada)
- 8.3.1 Nordion, Inc. (Canada) Comapny Information
- 8.3.2 Nordion, Inc. (Canada) Business Overview
- 8.3.3 Nordion, Inc. (Canada) PET Radiopharmaceuticals Sales, Value and Gross Margin (2020-2025)
- 8.3.4 Nordion, Inc. (Canada) PET Radiopharmaceuticals Product Portfolio
- 8.3.5 Nordion, Inc. (Canada) Recent Developments
- 8.4 Mallinckrodt plc (Ireland)
- 8.4.1 Mallinckrodt plc (Ireland) Comapny Information
- 8.4.2 Mallinckrodt plc (Ireland) Business Overview
- 8.4.3 Mallinckrodt plc (Ireland) PET Radiopharmaceuticals Sales, Value and Gross Margin (2020-2025)
- 8.4.4 Mallinckrodt plc (Ireland) PET Radiopharmaceuticals Product Portfolio
- 8.4.5 Mallinckrodt plc (Ireland) Recent Developments
- 8.5 Lantheus Medical Imaging, Inc. (U.S.)
- 8.5.1 Lantheus Medical Imaging, Inc. (U.S.) Comapny Information
- 8.5.2 Lantheus Medical Imaging, Inc. (U.S.) Business Overview
- 8.5.3 Lantheus Medical Imaging, Inc. (U.S.) PET Radiopharmaceuticals Sales, Value and Gross Margin (2020-2025)
- 8.5.4 Lantheus Medical Imaging, Inc. (U.S.) PET Radiopharmaceuticals Product Portfolio
- 8.5.5 Lantheus Medical Imaging, Inc. (U.S.) Recent Developments
- 8.6 IBA Molecular Imaging (Belgium)
- 8.6.1 IBA Molecular Imaging (Belgium) Comapny Information
- 8.6.2 IBA Molecular Imaging (Belgium) Business Overview
- 8.6.3 IBA Molecular Imaging (Belgium) PET Radiopharmaceuticals Sales, Value and Gross Margin (2020-2025)
- 8.6.4 IBA Molecular Imaging (Belgium) PET Radiopharmaceuticals Product Portfolio
- 8.6.5 IBA Molecular Imaging (Belgium) Recent Developments
- 8.7 GE Healthcare (U.K.)
- 8.7.1 GE Healthcare (U.K.) Comapny Information
- 8.7.2 GE Healthcare (U.K.) Business Overview
- 8.7.3 GE Healthcare (U.K.) PET Radiopharmaceuticals Sales, Value and Gross Margin (2020-2025)
- 8.7.4 GE Healthcare (U.K.) PET Radiopharmaceuticals Product Portfolio
- 8.7.5 GE Healthcare (U.K.) Recent Developments
- 8.8 Eczacibasi-Monrol Nuclear Products (Turkey)
- 8.8.1 Eczacibasi-Monrol Nuclear Products (Turkey) Comapny Information
- 8.8.2 Eczacibasi-Monrol Nuclear Products (Turkey) Business Overview
- 8.8.3 Eczacibasi-Monrol Nuclear Products (Turkey) PET Radiopharmaceuticals Sales, Value and Gross Margin (2020-2025)
- 8.8.4 Eczacibasi-Monrol Nuclear Products (Turkey) PET Radiopharmaceuticals Product Portfolio
- 8.8.5 Eczacibasi-Monrol Nuclear Products (Turkey) Recent Developments
- 8.9 Bracco Imaging S.p.A (Italy)
- 8.9.1 Bracco Imaging S.p.A (Italy) Comapny Information
- 8.9.2 Bracco Imaging S.p.A (Italy) Business Overview
- 8.9.3 Bracco Imaging S.p.A (Italy) PET Radiopharmaceuticals Sales, Value and Gross Margin (2020-2025)
- 8.9.4 Bracco Imaging S.p.A (Italy) PET Radiopharmaceuticals Product Portfolio
- 8.9.5 Bracco Imaging S.p.A (Italy) Recent Developments
- 8.10 Advanced Accelerator Applications S.A. (France)
- 8.10.1 Advanced Accelerator Applications S.A. (France) Comapny Information
- 8.10.2 Advanced Accelerator Applications S.A. (France) Business Overview
- 8.10.3 Advanced Accelerator Applications S.A. (France) PET Radiopharmaceuticals Sales, Value and Gross Margin (2020-2025)
- 8.10.4 Advanced Accelerator Applications S.A. (France) PET Radiopharmaceuticals Product Portfolio
- 8.10.5 Advanced Accelerator Applications S.A. (France) Recent Developments
- 9 Value Chain and Sales Channels Analysis
- 9.1 PET Radiopharmaceuticals Value Chain Analysis
- 9.1.1 PET Radiopharmaceuticals Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 PET Radiopharmaceuticals Sales Mode & Process
- 9.2 PET Radiopharmaceuticals Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 PET Radiopharmaceuticals Distributors
- 9.2.3 PET Radiopharmaceuticals Customers
- 10 Concluding Insights
- 11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.


